industry/academia translational oncology
Symposium Agenda
November 16, 2007
Location: Goldberg Auditorium, Moores UCSD Cancer Center
Time: 8:00am - 6:00pm

Organizers:
Dennis A. Carson, M.D., Director, Moores UCSD Cancer Center
Ida Deichaite, Ph.D., Director, Industry Relations, Moores UCSD Cancer Center

Symposium Chair:
David Cheresh, Ph.D., Associate Director for Translational Research and Professor of Pathology, Moores UCSD Cancer Center

Symposium Co-Chair:
Catriona Jamieson, M.D., Ph.D., Director, Stem Cell Research Program, Assistant Professor of Medicine, Moores UCSD Cancer Center

8:00AM
Registration and Continental Breakfast

8:30AM
Welcome and Overview

Dennis Carson, M.D., Director, Moores UCSD Cancer Center

8:45AM
Chair - David Cheresh, Ph.D., Associate Director for Translational Research and Professor of Pathology, Moores UCSD Cancer Center

Co-Chair – Catriona Jamieson, M.D., Ph.D., Director, Stem Cell Research Program, Assistant Professor of Medicine, Moores UCSD Cancer Center

9:00AM
The Bedside to Bench Aspects of Clinical Research: The Cancer Immunotherapy Model

Francesco P. Marincola, M.D., Chief, Infectious Disease and Immunogenetics Section, NIH

9:30AM
Development of Notch Pathway Inhibitors in Cancer

Peter R. Strack, Ph.D., Research Fellow, Merck
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15AM</td>
<td>Reversing MYC Induced Tumorigenesis</td>
<td>Dean W. Felsher, M.D., Ph.D., Associate Professor of Medicine, Stanford School of Medicine</td>
</tr>
<tr>
<td>10:45AM</td>
<td>Addressing Drug Resistance in the Era of Targeted Anticancer Chemotherapy</td>
<td>Frank Lee, Ph.D., Research Fellow, Oncology Drug Discovery, BMS</td>
</tr>
<tr>
<td>11:15AM</td>
<td>TSC-mTOR Pathway in Cell Growth and Cancer</td>
<td>Kun-Liang Guan, Ph.D., Professor, Department of Pharmacology, Moores UCSD Cancer Center</td>
</tr>
<tr>
<td>11:45PM</td>
<td>Jak-2 Therapeutic Inhibitors</td>
<td>Richard M. Soll, Ph.D., Vice President, Research &amp; Development, TargeGen</td>
</tr>
<tr>
<td>1:15PM</td>
<td>Lesson Learned: Biomarkers for Decision-Making in Oncology Clinical Trials</td>
<td>Wendy Levin, M.D., Associate Director, Oncology, Translational Medicine, Pfizer</td>
</tr>
<tr>
<td>2:15PM</td>
<td>Hsp 90 Inhibitors in Cancer</td>
<td>Chris Storgard, M.D., Director, Medical Research Oncology, Biogen Idec</td>
</tr>
<tr>
<td>2:45PM</td>
<td>Leukemia Specific Antigens - Their Roles in Pathogenesis and Potential for Use as Therapeutic Targets</td>
<td>Thomas J. Kipps, M.D., Ph.D., Deputy Director, Professor of Medicine, Moores UCSD Cancer Center</td>
</tr>
<tr>
<td>3:30PM</td>
<td>Panel: “Translational research in academia and industry – identifying the common goals and potential areas of divergence – moving forward, what are the key parameters to</td>
<td></td>
</tr>
</tbody>
</table>
increasing the supply of innovative, effective, oncology therapies to the patient?”

Panel moderator – Ivor Royston, M.D., Managing Member, Forward Ventures

Dennis A. Carson, M.D., Director, Moores UCSD Cancer Center

Thomas O. Daniel, M.D., President, Research, Celgene Corporation

Richard Houghten, Ph.D., President, Torrey Pines Institute for Molecular Studies, Inc

Francesco P. Marincola, M.D., Chief, Infectious Disease and Immunogenetics Section, NIH

John C. Reed, M.D., Ph.D., President and CEO, The Burnham Institute

Troy Wilson, Ph.D., J.D., President and CEO, Intellikine, Inc

4:30PM

Wine Reception